Using cangrelor to improve outcomes in patients with cardiogenic shock on ECMO

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the use of cangrelor, an anti-thrombotic medication, in patients experiencing cardiogenic shock or cardiac arrest who are receiving veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and undergoing percutaneous coronary intervention (PCI). The approach involves administering cangrelor alongside a low dose of bivalirudin, with regular monitoring of platelet function to ensure effective inhibition of platelet activity. The goal is to reduce bleeding risks while maintaining adequate antithrombotic effects during this critical treatment phase. Patients will transition to oral P2Y12 inhibitors after the cessation of VA-ECMO support.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patients aged ≥18 years;
* ACS-related CS/CA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;
* Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;
* Written informed consent

Exclusion Criteria:

* Overt uncontrollable bleeding;
* Suspected intra-cranial haemorrhage;
* Patients who received any dose of any oral P2Y12-inhibitors;
* Patients with known history of stroke or Transient Ischaemic Attack (TIA);
* Patients with known hypersensitivity to the active substance (cangrelor) or to any of its excipients;
* Pregnancy.

Where it's running

• IRCCS San Raffaele Hospital
  Milan, Italy, Italy Recruiting

Study contacts

• Study coordinator: Marina Pieri, MD
• Email: pieri.marina@hsr.it
• Phone: 0039 0226437722

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analyzing outcomes of extracorporeal life support after cardiac surgery

  This study looks at how extracorporeal life support helps patients with heart failure after heart surgery to see what factors affect their chances of recovery.

  Recruiting University of Florence · Florence · NCT04330651

• Factors Influencing Outcomes in ECMO and Impella Patients

  This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.

  Recruiting Gottsegen National Cardiovascular Institute · Budapest · NCT07885618

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Safety and Efficacy of an Extracorporeal Ventricular Assist System for Cardiogenic Shock

  This study tests whether an extracorporeal ventricular assist device can safely provide short-term heart support and help patients with cardiogenic shock or trouble weaning from bypass.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07769528

• Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care

  In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.

  Recruiting Leipzig Heart Science gGmbH · Leipzig, Saxony · NCT07762560

• CRP Apheresis for infarct-related cardiogenic shock

  This study tests whether selectively removing C-reactive protein with apheresis, in addition to standard care, helps people with cardiogenic shock after a heart attack.

  Recruiting Leipzig Heart Science gGmbH · Leipzig, Saxony · NCT07687017

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.